Phase 4 N=350 Comparing Intravenous Hydromorphone to Usual Care
Pain
Primary: Number of Participants Who Declined Additional Medication at 30 Minutes — 127; 106 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=212 A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus
Primary: Hemoglobin A1c (HbA1c) at 12 Weeks — 6.87; 6.93 percentage of HbA1c
Phase 3 N=100 Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806
Crohn's Disease
Primary: Number of Participants Who Achieved Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission Over Time — 67; 65; 67; 60 Participants
Phase 2 N=18 Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Epistaxis · Hereditary Hemorrhagic Telangiectasia
Primary: Severityof Epistaxis — -0.4578; -1.4375 units on a scale
Phase 4 N=114 A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
Pulmonary Embolism
Primary: Mean Duration of Hospitalization — 0.191; 1.393 Days — p=<.0001
Phase 4 N=128 Prospective, Double Blind, Placebo Control, Bariatric IV Ace
Obesity
Primary: Quality of Recovery-15 Patient Survey — 107.2; 108.6; 118.3; 117.1 units on a scale — p=0.59
Phase 2 N=27 Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Prostate Cancer
Primary: PSA Response — 14 Participants
Phase 3 N=466 A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change From Baseline to 26-week Endpoint in Hemoglobin A1c (HbA1c) — -0.82; -0.29 percentage of HbA1c
Phase 2 N=30 Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
Breast Cancer · Metastatic Cancer
Primary: Number of Patients With Objective Treatment Response (Complete or Partial) in the CNS — 2 Participants
N/A N=8 (Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?
Cystic Fibrosis
Primary: Change in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-Dependent Sweat Rate — 16.45; 6.60 percent change
Phase 2 N=231 A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Follicular Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) as Determined by Modified Response and Progression…
Phase 4 N=350 Safety and Efficacy of Intravenous Hydromorphone in Elderly Emergency Department Patients With Acute Severe Pain
Pain
Primary: Number of Patients With Successful Treatment — 127; 137; 26; 29 Participants
Phase 4 N=110 Prophylactic Pregabalin to Decrease Pain During Medical Abortion
Acute Pain
Primary: Maximum Pain Score Over Study Period — 5.0; 5.5 units on a scale — p=0.32
N/A N=43 Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Major Depressive Disorder
Primary: Fluorodopa Uptake Values in Brain Images of Aripiprazole Augmentation Responders — 1.297; 1.363; 1.333; 1.350 FDOPA ratio in the right medial caudate — p=0.029
Phase 3 N=350 Protocolized vs Discretionary Use of Opioids in Acute Pain
Pain
Primary: Percentage of Patients With Successful Treatment — 86.8; 76.6 Percentage of Participants